Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis

European Journal of Clinical Investigation

Volumn 28, Issue 8, 1998, Pages 687-692

  Suhr, O B ^a   Ando, Y ^a   Ohlsson, P I ^b   Olofsson, A ^b   Andersson, K ^b   Lundgren, E ^b   Ando, M ^c   Holmgren, G ^a  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b UMEÅ UNIVERSITY   (Sweden)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Amyloidosis genetics; Inborn errors of metabolism; Thiol conjugation chemistry; Transthyretin chemistry

Indexed keywords

PREALBUMIN;

AMYLOID NEUROPATHY; AMYLOIDOSIS; ARTICLE; CONJUGATION; CONTROLLED STUDY; GENETIC DISORDER; HUMAN; HUMAN TISSUE; INBORN ERROR OF METABOLISM; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; PRIORITY JOURNAL;

ADULT; AGED; AMYLOID NEUROPATHIES; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; METABOLISM, INBORN ERRORS; MIDDLE AGED; MOLECULAR WEIGHT; POINT MUTATION; PREALBUMIN; SULFHYDRYL COMPOUNDS;

EID: 0031850377     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00345.x     Document Type: Article

References (40)

1. Saraiva MJM, Birkin S, Costa PP, Goodman DS. Amyloid fibril protein in familial amyloid polyneuropathy, Portuguese type. Definition of molecular abnormality in transthyretin (prealbumin). J Clin Invest 1984; 74: 104-19.
2. Holmgren G, Costa PMP, Andersson C et al. Geographical distribution of TTR met30 carriers in Northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994; 31: 351-4.
3. Andrade C. A peculiar form of peripheral neuropathy. Familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 1952; 75: 408-27.
4. Andersson R. Familial amyloidosis with polyneuropathy: a clinical study based on patients living in northern Sweden. Acta Med Scan 1976; 198 (Suppl. 590): 1-76.
5. de Freitas A. The heart in Portuguese amyloidosis. Postgrad Med J 1986; 62: 601-5.
6. Ando Y, Araki S, Shimoda O, Kano T. Role of autonomie nerve function in patients with familial amyloidotic polyneuropathy as analyzed by laser doppler flowmetry, capsule hydrography, and cardiographic R-R interval. Muscle Nerve 1992; 15: 507-12.
7. Eriksson P, Boman K, Jacobsson B, Olofsson B. Cardiac arrhythmias in familial amyloid polyneuropathy during anaesthesia. Acta Anaesthesiol Scand 1986; 30: 317-20.
8. Olofsson BO, Suhr O, Niklasson U, Wiklund U, Bjerle P, Beckman A. Assessment of autonomic nerve function in familial amyloidotic polyneuropathy: a clinical study based on spectral analysis of heart rate variability. Amyloid 1994; 1: 138-42.
9. Steen L, Ek B. Familial amyloidosis with polyneuropathy. A long term follow up of 21 patients with special reference to gastrointestinal symptoms. Acta Med Scand 1984; 214: 387-97.
10. Suhr O, Danielsson Å, Holmgren G, Steen L. Malnutrition and gastrointestinal dysfunction as prognostic factors for survival in familial amyloidotic polyneuropathy. J Intern Med 1994; 235: 479-85.
11. Sandgren O. Ocular amyloidosis, with special reference to the hereditary forms with vitreous involvement. Surv Ophthalmol 1995; 40: 173-96.
12. Steen L, Wahlin A, Bjerle P, Holm S. Renal function in familial amyloidosis with polyneuropathy. Acta Med Scand 1982; 212: 233-6.
13. Nakazato M, Shiomi K, Miyazato M, Matsukura S. Type I familial amyloidotic polyneuropathy in Japan. Intern Med 1992; 31: 1335-8.
14. Ando Y, Araki S, Ando M. Transthyretin and familial amyloidotic polyneuropathy. Intern Med 1993; 32: 920-2.
15. Coutinho P, Martins da Silva A, Kopes Lima J, Resende Barbosa A. Forty years of experience with type I amyloid neuropathy. Review of 483 cases. In: Glenner G, Pinho e Costa P, Folcao de Freitas A, eds. Amyloid and Amyloidosis. Amsterdam: Excerpta Medica 1980: 88-98.
16. Holmgren G, Steen L, Ekstedt J et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-Met30). Clin Genet 1991; 40: 242-6.
17. Steen L, Holmgren G, Suhr O, Wikström L, Groth C-G, Ericzon BG. World-wide survey of liver transplantation in patients with familial amyloidotic polyneuropathy. Amyloid 1994; 1: 138-42.
18. Suhr OB, Holmgren G, Steen L et al. Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation 1995; 60: 933-8.
19. Parilla P, Ramirez P, Bueno F et al. Clinical improvement after liver transplantation for type I familial amyloid polyneuropathy. Br J Sur 1995; 82: 825-8.
20. Lewis W, Skinner M, Simms R, Jones L, Cohen A, Jenkins R. Orthotopic liver transplantation for familial amyloidotic polyneuropathy. Clin Transplantation 1994; 8: 107-10.
21. Kelly J, Lansbury P. A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid 1994; 1: 186-205.
22. Colon W, Kelly J. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochem 1992; 31: 8654-60.
23. Ando Y, Ohlsson P-I, Suhr O et al. A new simple and rapid screening method for variant transthyretin (TTR) related amyloidosis. Biochem Biophys Res Commun 1996; 228: 480-3.
24. Ranlov I, Ando Y, Ohlsson PI, Holmgren G, Ranløv PJ, Suhr OB. Rapid screening for amyloid related variant forms of transthyretin is possible by electrospray ionisation mass spectrometry. Eur J Clin Invest 1997; 27: 956-9.
25. Thylen C, Wahlqvist J, Haettner E, Sandgren O, Holmgren G, Lundgren E. Modifications of transthyretin in amyloid fibrils: analysis of amyloid from homozygous and heterozygous individuals with the Met30 mutation. EMBO J 1993; 12: 743-8.
26. Ando Y, Nyhlin N, Suhr O et al. Oxidative stress is found in amyloid deposits. Biochem Biophys Res Commun 1997; 232: 497-502.
27. Mancini G, Carbonara A, Heremans J. Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochem 1965; 2: 235-40.
28. Holmgren G, Lundgren E, Kangawa K et al. Diagnostic radioimmunoassay and DNA-analysis in Swedish and Japanese patients with familial amyloidotic polyneuropathy. Homozygosity for the TTR met30 gene. Acta Neurol Scand 1993; 87: 124-7.
29. Lai Z, Colon W, Kelly JW. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. Biochemistry 1996; 35: 6470-82.
30. Ikegawa S, Tanase S, Araki S, Morino Y. Quantitative detection of a variant prealbumin associated with type 1 familial amyloidotic polyneuropathy (Japanese type) by high performance liquid chromatography. Clin Chim Acta 1987; 167: 165-72.
31. Era S, Kuwata K, Imai H, Nakamura K, Hayashi T, Sogami M. Age-related change in redox state of human serum albumin. Biochim Biophys Acta 1995; 1247: 12-6.
32. Gustavsson Å, Engström U, Westermark P. Mechanisms of transthyretin amyloidogenesis. Antigenic mapping of transthyretin purified from plasma and amyloidfibrils and within in situ tissue localizations. Am J Pathol 1994; 144: 1301-11.
33. Bleiberg-Daniel F, Le Moullac B, Maire J, Wada S. Failure of tryptophan deficiency to reduce specifically serum levels of transthyretin or albumin in rats. J Nutr 1990; 120: 1610-6.
34. Le Moullac B, Gouache P, Bleiberg-Daniel F. Regulation of hepatic transthyretin messenger RNA levels during moderate protein food restriction in rats. J Nutr 1992; 122: 864-70.
35. Golden M. Transport proteins as indices of protein status. Am J Clin Nutrition 1982; 35: 1159-65.
36. Shetty P, Watrasiewicz K, Jung R, James W. Rapid turn-over transport proteins: an index of subclinical protein energy malnutrition. Lancet 1979; ii: 230-2.
37. Jonas R, Flanagan P, Forstner G. Pathogenesis of mucosal injury in the blind loop syndrome. Brush border enzyme activity and glycoprotein degradation. J Clin Invest 1977; 60: 1321-30.
38. Suhr OB, Danielsson Å, Rydh A, Nyhlin N, Hietala SO, Steen L. Impact of gastrointestinal dysfunction on survival after liver transplantation for familial amyloidotic polyneuropathy. Dig Dis Sci 1996; 41: 1909-14.
39. Terry CJ, Damas AM, Oliveira P et al. Structure of Met30 variant of transthyretin and its amyloidogenic implications. EMBO J 1993; 12: 735-41.
40. Sano M, Ernesto C, Thomas RG et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. N Engl J Med 1997; 336: 1216-22.